Skip to main content
Sinopharm Tech Holdings Limited logo

Sinopharm Tech Holdings Limited — Investor Relations & Filings

Ticker · 8156 ISIN · KYG2159V1418 HKEX Wholesale and retail trade
Open in API
Filings indexed 1,471 across all filing types
Latest filing 2023-11-16 Audit Report / Informat…
Country HK Hong Kong
Listing HKEX 8156

About Sinopharm Tech Holdings Limited

http://www.sinopharmtech.com.hk

Sinopharm Tech Holdings Limited is an investment holding company primarily engaged in the big health industry and pharmaceutical supply chain business. The company focuses on the trading and distribution of medical and related products, including Chinese patent medicines and health products, targeting the market in the PRC. It develops its supply chain operations using "Internet Plus" services, leveraging technology to provide value-added services to industry operators and product suppliers. The Group is also integrating AI analytics to enhance its operations within the healthcare sector.

Recent filings

Filing Released Lang Actions
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 30 JUNE 2023
Audit Report / Information Classification · 95% confidence The document is a detailed announcement discussing the audit qualification issues related to the annual report for the year ended 30 June 2023 of Sinopharm Tech Holdings Limited. It references the annual report and the auditor's qualified opinion, elaborates on specific audit issues affecting the consolidated financial statements, and discusses management's position and plans to address these audit modifications. The document is not the annual report itself but a supplemental announcement related to the audit report and the annual report. It contains substantive financial details and audit-related information but is primarily an announcement supplementing the annual report and audit findings rather than the full annual report or standalone audit report. Given the detailed discussion of audit issues and the auditor's qualified opinion, the document fits best under Audit Report / Information (AR) as it focuses on audit modifications and their impact on the financial statements, rather than being the full annual report or a simple announcement of report publication. FY 2023
2023-11-16 English
INSIDE INFORMATION - ADJOURNMENT OF WINDING-UP PETITION HEARING
Legal Proceedings Report Classification · 95% confidence The document is an announcement regarding the adjournment of a winding-up petition hearing involving Sinopharm Tech Holdings Limited. It references compliance with the GEM Listing Rules and Inside Information Provisions, indicating it is a regulatory announcement. The content is brief (3199 characters), focused on a legal proceeding update, and does not contain financial statements or detailed financial data. It is not a full report but a regulatory announcement about a legal matter. Therefore, it fits best under Legal Proceedings Report (LTR).
2023-11-15 English
FIRST QUARTERLY REPORT 2023/2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Sinopharm Tech Holdings Limited FIRST QUARTERLY REPORT 2023/2024' and contains detailed unaudited consolidated financial results for the three months ended 30 September 2023. It includes comprehensive financial statements such as profit or loss, comprehensive income, notes on accounting policies, revenue breakdown, income tax expense, earnings per share, and movement of reserves. The length of the document is substantial (15,000 characters) and it contains actual financial data and analysis for a quarterly period. The presence of detailed financial statements and notes confirms this is a quarterly financial report rather than a brief announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2023-11-14 English
FIRST QUARTERLY RESULTS ANNOUNCEMENT FOR THE THREE MONTHS ENDED 30 SEPTEMBER 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FIRST QUARTERLY RESULTS ANNOUNCEMENT FOR THE THREE MONTHS ENDED 30 SEPTEMBER 2023' and contains detailed unaudited consolidated financial results, including profit and loss statements, income tax expense, earnings per share, and notes to the unaudited condensed consolidated financial statements. It explicitly states it is the 'First Quarterly Report 2023/2024' and includes substantive financial data and analysis for the quarter ended 30 September 2023. The length of the document (15,000 characters) and the presence of detailed financial statements confirm it is a full quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2023-11-14 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report on movements in securities for Sinopharm Tech Holdings Limited, specifically focusing on share capital, issued shares, share options, and confirmations related to securities issued. It includes data on share consolidation, share options outstanding, and confirmations by the company secretary regarding compliance with listing rules. The document is addressed to the Hong Kong Exchanges and Clearing Limited and references specific listing rules (Chapter 19B, Main Board Rule 13.25A / GEM Rule 17.27A). It is a regulatory submission detailing share capital changes and confirmations rather than a financial report, earnings release, or management discussion. It does not contain financial statements or earnings data, nor is it an announcement of voting results or a proxy statement. The content fits the category of a regulatory filing related to share capital movements and confirmations under exchange rules. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-11-06 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from Sinopharm Tech Holdings Limited regarding the date of a forthcoming board meeting to approve and publish the unaudited consolidated results for the quarter ended 30 September 2023 and to consider dividend payment. The text explicitly states it is an announcement of the meeting date and the intended approval of financial results, not the financial results themselves. The document length is short (2412 characters), and it does not contain actual financial data or detailed financial statements. It is a notice about an upcoming event related to financial reporting, not the report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2023-11-02 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.